115 related articles for article (PubMed ID: 32818862)
21. Cadmium-induced malignant transformation of human prostate epithelial cells.
Achanzar WE; Diwan BA; Liu J; Quader ST; Webber MM; Waalkes MP
Cancer Res; 2001 Jan; 61(2):455-8. PubMed ID: 11212230
[TBL] [Abstract][Full Text] [Related]
22. Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate.
Ogunlewe JO; Osegbe DN
Cancer; 1989 Apr; 63(7):1388-92. PubMed ID: 2465818
[TBL] [Abstract][Full Text] [Related]
23. Induction of endoplasmic reticulum stress might be responsible for defective autophagy in cadmium-induced prostate carcinogenesis.
Kolluru V; Tyagi A; Chandrasekaran B; Ankem M; Damodaran C
Toxicol Appl Pharmacol; 2019 Jun; 373():62-68. PubMed ID: 31002860
[TBL] [Abstract][Full Text] [Related]
24. Cadmium concentration and metallothionein expression in prostate cancer and benign prostatic hyperplasia of humans.
Lee JD; Wu SM; Lu LY; Yang YT; Jeng SY
J Formos Med Assoc; 2009 Jul; 108(7):554-9. PubMed ID: 19586829
[TBL] [Abstract][Full Text] [Related]
25. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
Kalantari E; Abolhasani M; Roudi R; Farajollahi MM; Farhad S; Madjd Z; Askarian-Amiri S; Mohsenzadegan M
Int J Exp Pathol; 2019 Apr; 100(2):123-132. PubMed ID: 31090157
[TBL] [Abstract][Full Text] [Related]
26. Zinc and cadmium in cell fractions of prostatic cancer tissues of different histological grading in comparison to BPH and normal prostate.
Feustel A; Wennrich R
Urol Res; 1984; 12(2):147-50. PubMed ID: 6204433
[TBL] [Abstract][Full Text] [Related]
27. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
28. Determination of the distribution of zinc and cadmium in cellular fractions of BPH, normal prostate and prostatic cancers of different histologies by atomic and laser absorption spectrometry in tissue slices.
Feustel A; Wennrich R
Urol Res; 1984; 12(5):253-6. PubMed ID: 6083653
[TBL] [Abstract][Full Text] [Related]
29. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.
Cordon-Cardo C; Koff A; Drobnjak M; Capodieci P; Osman I; Millard SS; Gaudin PB; Fazzari M; Zhang ZF; Massague J; Scher HI
J Natl Cancer Inst; 1998 Sep; 90(17):1284-91. PubMed ID: 9731735
[TBL] [Abstract][Full Text] [Related]
30. A single low dose of cadmium exposure induces benign prostate hyperplasia like condition in rat: A novel benign prostate hyperplasia rodent model.
Prajapati A; Rao A; Patel J; Gupta S; Gupta S
Exp Biol Med (Maywood); 2014 Jul; 239(7):829-841. PubMed ID: 24872436
[TBL] [Abstract][Full Text] [Related]
31. Expression of estrogen receptor-B ( ER-B ) in bengin and malignant prostatic epithelial cells and its correlation with the clinico-pathological features.
Gabal SM; Habib FM; Helmy DO; Ibrahim MF
J Egypt Natl Canc Inst; 2007 Dec; 19(4):239-48. PubMed ID: 19672287
[TBL] [Abstract][Full Text] [Related]
32. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
[TBL] [Abstract][Full Text] [Related]
33. Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.
Qaiser F; Trembley JH; Sadiq S; Muhammad I; Younis R; Hashmi SN; Murtaza B; Rector TS; Naveed AK; Ahmed K
Mol Cell Biochem; 2016 Sep; 420(1-2):43-51. PubMed ID: 27435858
[TBL] [Abstract][Full Text] [Related]
34. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.
Royuela M; De Miguel MP; Bethencourt FR; Sanchez-Chapado M; Fraile B; Paniagua R
Growth Factors; 1998; 16(2):101-10. PubMed ID: 9932228
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
[TBL] [Abstract][Full Text] [Related]
37. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors.
Untergasser G; Rumpold H; Hermann M; Dirnhofer S; Jilg G; Berger P
Exp Gerontol; 1999 Apr; 34(2):275-87. PubMed ID: 10363793
[TBL] [Abstract][Full Text] [Related]
38. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
39. Association of cadmium and lead with antioxidant status and incidence of benign prostatic hyperplasia in patients of Western India.
Pandya C; Gupta S; Pillai P; Bhandarkar A; Khan A; Bhan A; Prajapati A; Gupta S
Biol Trace Elem Res; 2013 Jun; 152(3):316-26. PubMed ID: 23479318
[TBL] [Abstract][Full Text] [Related]
40. CYP1A1 gene polymorphism and heavy metal analyses in benign prostatic hyperplasia and prostate cancer: An explorative case-control study.
Singh V; Madeshiya AK; Ansari NG; Singh MK; Abhishek A
Urol Oncol; 2023 Aug; 41(8):355.e9-355.e17. PubMed ID: 37277283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
